Literature DB >> 15166950

Successful treatment of post-exertion acute myocardial infarction by primary angioplasty and stenting in a patient with antiphospholipid antibody syndrome.

Gerardo Musuraca1, Ferdinando Imperadore, Clotilde Terraneo, Piergiuseppe De Girolamo, Claudio Cemin, Roberto Bonmassari, Giuseppe Vergara.   

Abstract

Antiphospholipid syndrome is a disorder characterized by arterial and venous thromboses, thrombocytopaenia and stroke. Acute myocardial infarction is rarely associated with this syndrome. The treatment of these patients is a clinical challenge. This report is about a patient with antiphospholipid syndrome presenting with an acute myocardial infarction after an exercise test. The infarct-related coronary artery was successfully revascularized by primary angioplasty and stenting without any major bleeding complications. We think that the physical exertion could have favoured acute coronary thrombosis in this particular setting. Copyright 2004 Lippincott Williams and Wilkins

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166950     DOI: 10.1097/00001721-200401000-00015

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis.

Authors:  O Morel; L Jesel; J M Freyssinet; F Toti
Journal:  Thromb J       Date:  2005-10-11

2.  Recurrent stent thrombosis in a patient with antiphospholipid syndrome and dual anti-platelet therapy non-responsiveness.

Authors:  You-Hong Lee; Hyoung-Mo Yang; Seung-Jea Tahk; You-Sun Hong; Jin-Sun Park; Kyoung-Woo Seo; Yong-Woo Choi; Choong-Kyun Noh
Journal:  Korean Circ J       Date:  2015-01-26       Impact factor: 3.243

3.  Therapeutic challenges after successful thrombectomy in a patient with an antiphospholipid syndrome associated M1-occlusion: A case report.

Authors:  Katharina Stadler; Johannes S Mutzenbach; Gudrun Kalss; Johann Sellner; Abdul R Al-Schameri; Eugen Trinka; Monika Killer-Oberpfalzer
Journal:  Interv Neuroradiol       Date:  2015-07-01       Impact factor: 1.610

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.